Go Pro
→ Porter flew 3,300 miles to investigate this system (From Porter & Company) (Ad)tc pixel Free URGN Stock Alerts

Urogen Pharma (URGN) Financials

Urogen Pharma logo
$45.22 +0.80 (+1.80%)
As of 03:39 PM Eastern
Compare
Annual Income Statements for Urogen Pharma

Annual Income Statements for Urogen Pharma

This table shows Urogen Pharma's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -13 -1.94 -20 -76 -105 -128 -111 -110 -102 -127 -154
Consolidated Net Income / (Loss)		 -13 -1.94 -20 -76 -105 -128 -111 -110 -102 -127 -153
Net Income / (Loss) Continuing Operations		 -13 -1.94 -20 -76 -105 -128 -111 -110 -102 -127 -153
Total Pre-Tax Income 		-13 -1.94 -20 -76 -105 -125 -109 -108 -98 -124 -153
Total Operating Income		 -12 0.80 -20 -77 -109 -127 -92 -79 -66 -97 -125
Total Gross Profit		 0.00 18 7.56 -0.68 0.02 11 43 57 73 82 97
Total Revenue		 0.00 18 8.16 1.13 0.02 12 48 64 83 90 110
Operating Revenue		 0.00 18 8.16 1.13 0.02 12 48 64 83 90 110
Total Cost of Revenue		 0.00 0.03 0.60 1.80 0.00 1.01 5.16 7.65 9.36 8.88 12
Operating Cost of Revenue		 0.00 0.03 0.60 1.80 0.00 1.01 5.16 7.65 9.36 8.88 12
Total Operating Expenses		 12 17 28 77 109 138 135 136 139 178 222
Selling, General & Admin Expense		 1.90 6.42 8.81 40 60 90 88 83 93 121 155
Research & Development Expense		 11 10 19 37 49 47 48 53 46 57 67
Total Other Income / (Expense), net		 -0.28 -2.74 -0.03 1.65 4.33 1.63 -17 -29 -33 -27 -29
Interest Expense		 - - - - - - 0.00 8.44 15 13 15
Interest & Investment Income		 - - -0.03 1.65 4.33 1.63 0.21 1.01 3.48 8.67 5.30
Other Income / (Expense), net		 -0.28 -2.74 - - - 0.00 -17 -22 -22 -23 -19
Income Tax Expense		 0.00 - 0.02 0.13 0.00 3.37 1.45 1.76 3.92 2.83 0.08
Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders)		 - - 0.00 0.00 - 0.01 - 0.08 -0.12 -0.04 0.04
Basic Earnings per Share		 ($5.88) ($1.91) ($2.14) ($4.80) ($5.12) ($5.90) ($4.96) ($4.81) ($3.55) ($2.96) ($3.19)
Weighted Average Basic Shares Outstanding		 2.30M 2.31M 9.72M 15.75M 20.53M 21.78M 22.35M 22.81M 28.83M 42.88M 48.12M
Weighted Average Diluted Shares Outstanding		 2.30M 2.31M 9.72M 15.75M 20.53M 21.78M 22.35M 23.44M 34.12M 46.09M 48.68M
Weighted Average Basic & Diluted Shares Outstanding		 2.30M 2.31M 9.72M 15.75M 20.53M 21.78M 22.35M 23.44M 34.12M 46.09M 48.68M

Quarterly Income Statements for Urogen Pharma

This table shows Urogen Pharma's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Income / (Loss) Attributable to Common Shareholders		 -26 -32 -33 -23 -38 -44 -50 -33 -26 -24 -14
Consolidated Net Income / (Loss)		 -26 -32 -33 -24 -38 -44 -50 -33 -26 -24 -14
Net Income / (Loss) Continuing Operations		 -26 -32 -33 -24 -38 -44 -50 -33 -26 -24 -14
Total Pre-Tax Income 		-22 -32 -33 -24 -35 -43 -49 -34 -27 -28 -8.72
Total Operating Income		 -15 -26 -26 -18 -28 -37 -41 -27 -19 -20 0.11
Total Gross Profit		 21 17 20 23 22 18 21 24 35 47 66
Total Revenue		 24 19 22 25 25 20 24 27 38 51 72
Operating Revenue		 24 19 22 25 25 20 24 27 38 51 72
Total Cost of Revenue		 2.29 1.73 2.23 2.45 2.47 2.33 3.55 3.28 3.29 4.14 6.57
Operating Cost of Revenue		 2.29 1.73 2.23 2.45 2.47 2.33 3.55 3.28 3.29 4.14 6.57
Total Operating Expenses		 36 43 45 40 50 55 62 52 54 67 66
Selling, General & Admin Expense		 25 27 30 29 35 35 43 38 39 51 48
Research & Development Expense		 11 15 15 11 15 20 19 14 14 16 17
Total Other Income / (Expense), net		 -7.55 -6.49 -7.53 -6.04 -7.21 -6.54 -7.48 -7.02 -7.52 -8.08 -8.83
Interest Expense		 3.59 2.45 3.46 2.72 3.89 4.07 4.13 3.37 3.77 4.19 4.89
Interest & Investment Income		 1.54 1.62 1.71 2.60 2.75 2.11 1.30 0.98 0.90 0.61 0.60
Other Income / (Expense), net		 -5.51 -5.66 -5.77 -5.92 -6.06 -4.58 -4.64 -4.62 -4.66 -4.51 -4.55
Income Tax Expense		 3.85 0.05 0.04 0.09 2.65 0.39 1.02 -1.05 -0.28 -4.77 5.63
Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders)		 -0.15 0.05 -0.01 -0.27 0.18 0.04 0.01 -0.02 0.00 0.01 0.01
Basic Earnings per Share		 ($0.54) ($0.87) ($0.82) ($0.51) ($0.53) ($0.92) ($1.05) ($0.69) ($0.53) ($0.47) ($0.28)
Weighted Average Basic Shares Outstanding		 28.83M 37.06M 40.50M 46.78M 42.88M 47.42M 47.74M 48.06M 48.12M 50.18M 50.38M
Weighted Average Diluted Shares Outstanding		 34.12M 36.13M 42.11M 42.20M 46.09M 46.11M 46.26M 46.81M 48.68M 48.72M 48.88M
Weighted Average Basic & Diluted Shares Outstanding		 34.12M 36.13M 42.11M 42.20M 46.09M 46.11M 46.26M 46.81M 48.68M 48.72M 48.88M

Annual Cash Flow Statements for Urogen Pharma

This table details how cash moves in and out of Urogen Pharma's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 14 3.46 16 64 -51 3.88 -8.50 11 40 77 -61
Net Cash From Operating Activities		 -7.18 4.19 -9.57 -37 -71 -106 -85 -88 -76 -97 -162
Net Cash From Continuing Operating Activities		 -7.18 4.19 -9.57 -37 -71 -106 -85 -88 -76 -97 -162
Net Income / (Loss) Continuing Operations		 -13 -1.94 -20 -76 -105 -128 -111 -110 -102 -127 -153
Consolidated Net Income / (Loss)		 -13 -1.94 -20 -76 -105 -128 -111 -110 -102 -127 -153
Depreciation Expense		 0.11 0.21 0.21 0.42 0.30 0.42 0.83 0.92 0.80 0.33 0.31
Amortization Expense		 - - 0.00 0.00 0.46 0.44 1.42 2.15 -0.02 -3.34 0.71
Non-Cash Adjustments To Reconcile Net Income		 4.79 4.71 6.47 31 29 28 37 24 21 27 18
Changes in Operating Assets and Liabilities, net		 0.61 1.21 3.76 7.16 4.32 -6.37 -13 -5.18 4.32 5.92 -28
Net Cash From Investing Activities		 -0.30 -0.72 -36 35 -146 93 4.07 1.06 -0.95 -21 62
Net Cash From Continuing Investing Activities		 -0.30 -0.72 -36 35 -146 93 4.07 1.06 -0.95 -21 62
Purchase of Property, Plant & Equipment		 -0.30 -0.70 -0.27 -0.56 -0.33 -1.22 -0.75 -0.25 -0.19 -0.30 -0.29
Purchase of Investments		 0.00 - -36 -0.05 -198 -30 -52 -63 -50 -128 -77
Sale and/or Maturity of Investments		 - - 0.00 36 53 124 57 64 49 108 139
Net Cash From Financing Activities		 22 -0.01 62 66 165 17 72 97 117 195 40
Net Cash From Continuing Financing Activities		 22 -0.01 62 66 165 17 72 97 117 195 40
Issuance of Debt		 - - 0.04 - - - 0.00 96 0.00 24 0.00
Issuance of Common Equity		 0.00 - 61 64 162 16 - 0.00 116 170 40
Other Financing Activities, net		 0.00 0.57 0.79 2.40 3.66 0.74 72 1.51 0.87 0.32 0.12

Quarterly Cash Flow Statements for Urogen Pharma

This table details how cash moves in and out of Urogen Pharma's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Change in Cash & Equivalents		 -24 36 89 -95 47 -68 -11 -2.60 21 -0.80 -31
Net Cash From Operating Activities		 -13 -32 -24 -28 -14 -42 -40 -42 -38 -45 -33
Net Cash From Continuing Operating Activities		 -13 -32 -24 -28 -14 -42 -40 -42 -38 -45 -33
Net Income / (Loss) Continuing Operations		 -26 -32 -33 -24 -38 -44 -50 -33 -26 -24 -14
Consolidated Net Income / (Loss)		 -26 -32 -33 -24 -38 -44 -50 -33 -26 -24 -14
Depreciation Expense		 0.19 0.12 0.07 0.07 0.07 0.07 0.08 0.08 0.08 0.08 0.08
Amortization Expense		 -1.05 -0.92 0.12 -1.47 -1.07 0.03 0.05 0.00 0.63 2.58 -0.48
Non-Cash Adjustments To Reconcile Net Income		 6.17 5.11 7.20 6.56 9.37 3.57 3.40 3.87 6.37 5.63 6.37
Changes in Operating Assets and Liabilities, net		 7.80 -3.76 2.27 -9.15 16 -1.85 6.59 -13 -19 -30 -25
Net Cash From Investing Activities		 -11 14 12 -107 61 -26 28 31 28 -21 1.67
Net Cash From Continuing Investing Activities		 -11 14 12 -107 61 -26 28 31 28 -21 1.67
Purchase of Property, Plant & Equipment		 -0.06 0.00 -0.08 -0.10 -0.12 -0.04 -0.14 -0.09 -0.02 -0.05 -0.06
Sale and/or Maturity of Investments		 3.54 14 12 12 70 40 30 40 28 4.15 1.73
Net Cash From Financing Activities		 0.04 55 100 40 0.07 0.03 0.30 8.27 31 65 0.50
Net Cash From Continuing Financing Activities		 0.04 55 100 40 0.07 0.03 0.30 8.27 31 66 0.18
Other Financing Activities, net		 0.04 0.00 0.14 0.12 0.07 0.03 0.30 0.30 -0.51 0.18 0.18

Annual Balance Sheets for Urogen Pharma

This table presents Urogen Pharma's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 23 76 104 202 122 120 136 178 286 200
Total Current Assets		 22 74 102 149 116 114 129 169 276 186
Cash & Equivalents		 21 37 101 50 53 44 55 95 172 111
Restricted Cash		 0.10 0.20 0.25 0.52 1.23 1.23 0.81 0.82 1.08 1.35
Short-Term Investments		 0.00 36 0.00 97 49 45 45 42 65 9.71
Accounts Receivable		 0.08 - - 0.00 7.05 12 13 15 20 33
Inventories, net		 0.11 0.32 - 0.00 1.96 4.83 4.33 5.67 9.23 16
Prepaid Expenses		 0.40 0.96 0.67 1.03 3.36 7.48 11 10 8.85 15
Plant, Property, & Equipment, net		 0.74 0.81 0.95 0.98 2.05 1.97 1.30 0.69 0.66 0.64
Total Noncurrent Assets		 0.27 0.27 0.37 53 4.34 3.39 5.42 8.44 8.92 14
Long-Term Investments		 0.02 0.03 0.05 49 2.12 0.90 0.22 4.73 5.20 0.18
Noncurrent Note & Lease Receivables		 - - - - - - - - 3.13 5.38
Other Noncurrent Operating Assets		 0.25 0.24 0.32 4.00 2.22 2.49 5.19 3.71 0.59 8.24
Total Liabilities & Shareholders' Equity		 23 76 104 202 122 120 136 178 286 200
Total Liabilities		 6.75 7.04 13 22 26 111 225 244 295 306
Total Current Liabilities		 3.14 7.04 13 19 21 22 24 31 46 46
Accounts Payable		 1.88 4.44 8.54 11 10 12 12 17 27 28
Current Employee Benefit Liabilities		 0.69 1.95 4.93 6.71 9.55 6.95 8.26 11 11 14
Other Current Liabilities		 0.57 - 0.00 1.59 1.86 3.33 3.28 3.86 7.95 5.19
Total Noncurrent Liabilities		 3.61 0.00 0.00 2.60 4.21 89 201 212 249 260
Long-Term Debt		 - - - - - 0.00 98 99 122 122
Capital Lease Obligations		 - - - - - - - 0.84 1.65 3.48
Noncurrent Deferred & Payable Income Tax Liabilities		 - - - 0.00 2.72 2.84 3.02 3.19 3.79 3.90
Other Noncurrent Operating Liabilities		 3.61 - 0.00 2.60 1.50 86 101 110 121 130
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 16 69 90 180 96 8.41 -89 -65 -8.80 -105
Total Preferred & Common Equity		 16 69 90 180 96 8.41 -89 -65 -8.80 -105
Total Common Equity		 16 69 90 180 96 8.41 -89 -65 -8.80 -105
Common Stock		 44 116 213 408 453 476 488 614 797 854
Retained Earnings		 -27 -47 -123 -228 -357 -467 -577 -679 -806 -960
Accumulated Other Comprehensive Income / (Loss)		 - - 0.00 0.28 0.27 -0.03 -0.11 0.01 0.06 0.02

Quarterly Balance Sheets for Urogen Pharma

This table presents Urogen Pharma's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026
Period end date 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026
Total Assets		 113 95 194 201 282 302 248 209 185 254 253
Total Current Assets		 96 81 182 197 279 295 237 197 169 237 235
Cash & Equivalents		 37 20 119 131 220 125 104 93 90 110 79
Restricted Cash		 0.81 0.82 0.82 0.82 0.83 1.07 1.08 1.08 1.35 1.33 1.33
Short-Term Investments		 29 27 28 33 21 125 92 64 37 30 29
Accounts Receivable		 12 16 13 14 17 23 20 20 20 55 89
Inventories, net		 5.47 4.99 5.00 7.24 7.44 7.59 7.59 7.13 8.34 21 25
Prepaid Expenses		 12 13 16 10 12 14 13 12 12 20 13
Plant, Property, & Equipment, net		 1.10 0.91 0.82 0.57 0.58 0.61 0.63 0.69 0.70 0.62 0.60
Total Noncurrent Assets		 16 13 11 3.25 2.30 6.24 9.81 11 16 16 17
Long-Term Investments		 10 8.19 6.73 0.71 0.38 4.82 4.69 4.81 0.56 0.18 0.18
Noncurrent Note & Lease Receivables		 - - - - - - 4.75 5.55 8.49 7.94 4.82
Other Noncurrent Operating Assets		 5.49 4.92 3.96 2.54 1.92 1.42 0.37 0.80 6.76 7.49 12
Total Liabilities & Shareholders' Equity		 113 95 194 201 282 302 248 209 185 254 253
Total Liabilities		 230 234 236 241 252 276 294 302 300 378 385
Total Current Liabilities		 25 27 26 26 34 33 42 48 42 51 62
Accounts Payable		 17 16 14 18 24 20 30 31 26 35 40
Current Employee Benefit Liabilities		 4.92 6.72 8.15 4.99 6.85 9.03 6.97 12 11 9.84 12
Other Current Liabilities		 3.19 3.64 3.55 3.20 3.62 4.07 4.71 4.94 4.96 5.45 9.72
Total Noncurrent Liabilities		 204 207 210 214 217 244 252 255 258 327 323
Long-Term Debt		 98 98 99 98 98 122 122 123 122 190 189
Capital Lease Obligations		 - - - - - - 2.84 3.41 6.24 5.65 2.94
Noncurrent Deferred & Payable Income Tax Liabilities		 3.02 3.02 3.02 3.19 3.19 3.19 3.79 3.79 3.79 3.90 3.90
Other Noncurrent Operating Liabilities		 103 106 108 114 116 119 123 125 126 128 127
Commitments & Contingencies		 0.00 0.00 0.00 0.00 - 0.00 - 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -117 -138 -42 -40 30 26 -46 -93 -115 -124 -132
Total Preferred & Common Equity		 -117 -138 -42 -40 30 26 -46 -93 -115 -124 -132
Total Common Equity		 -117 -138 -42 -40 30 26 -46 -93 -115 -124 -132
Common Stock		 491 493 611 672 775 794 804 807 818 859 865
Retained Earnings		 -607 -631 -653 -712 -745 -769 -850 -900 -933 -983 -998
Accumulated Other Comprehensive Income / (Loss)		 -0.05 -0.15 -0.13 -0.04 -0.03 0.24 0.01 0.01 0.02 0.01 -0.00

Annual Metrics And Ratios for Urogen Pharma

This table displays calculated financial ratios and metrics derived from Urogen Pharma's official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 - - - - - - - - - - 46,808,892.00
DEI Adjusted Shares Outstanding		 - - - - - - - - - - 46,808,892.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - - - - -3.28
Growth Metrics		 - - - - - - - - - - -
Profitability Metrics		 - - - - - - - - - - -
Net Operating Profit after Tax (NOPAT)		 -8.69 0.56 -14 -54 -77 -89 -65 -55 -46 -68 -87
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - - -134.20% -59.12% -382.38%
Earnings before Interest and Taxes (EBIT)		 -13 -1.94 -20 -77 -109 -127 -110 -101 -87 -120 -143
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -13 -1.73 -20 -77 -109 -126 -107 -98 -86 -123 -142
Valuation Ratios		 - - - - - - - - - - -
Leverage & Solvency		 - - - - - - - - - - -
Liquidity Ratios		 - - - - - - - - - - -
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 5.73 -14 -47 -72 -96 9.24 -45 -30 -48 -117
Efficiency Ratios		 - - - - - - - - - - -
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 0.00 -5.17 -4.71 -12 -16 -9.01 -83 -93 -108 -128 -99
Increase / (Decrease) in Invested Capital		 0.00 -5.17 0.46 -6.82 -4.55 7.07 -74 -9.97 -16 -20 29
Book Value per Share		 $0.00 $7.07 $7.05 $6.55 $8.59 $4.36 $0.38 ($3.87) ($2.11) ($0.21) ($2.25)
Tangible Book Value per Share		 $0.00 $7.07 $7.05 $6.55 $8.59 $4.36 $0.38 ($3.87) ($2.11) ($0.21) ($2.25)
Total Capital		 0.00 16 69 90 180 96 8.41 8.18 34 115 23
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 98 99 123 128
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 98 99 123 128
Net Debt		 0.00 -21 -73 -102 -196 -105 -91 -3.46 -43 -120 6.35
Capital Expenditures (CapEx)		 0.30 0.70 0.27 0.56 0.33 1.22 0.75 0.25 0.19 0.30 0.29
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 -2.55 -5.76 -13 -18 -9.06 1.65 4.21 0.19 -7.58 18
Debt-free Net Working Capital (DFNWC)		 0.00 19 67 89 129 94 92 105 138 230 140
Net Working Capital (NWC)		 0.00 19 67 89 129 94 92 105 138 230 140
Net Nonoperating Expense (NNE)		 4.00 2.50 6.04 22 29 40 46 54 56 59 66
Net Nonoperating Obligations (NNO)		 0.00 -21 -73 -102 -196 -105 -91 -3.46 -43 -120 6.35
Total Depreciation and Amortization (D&A)		 0.11 0.21 0.21 0.42 0.75 0.86 2.25 3.07 0.78 -3.01 1.01
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($1.91) $0.00 ($4.80) ($5.12) ($5.90) ($4.96) ($4.81) ($3.55) ($2.96) ($3.19)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 2.31M 0.00 20.48M 21.15M 22.27M 22.67M 22.81M 28.83M 42.88M 48.12M
Adjusted Diluted Earnings per Share		 $0.00 ($1.91) $0.00 ($4.80) ($5.12) ($5.90) ($4.96) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 2.31M 0.00 20.48M 21.15M 22.27M 22.67M 23.44M 34.12M 46.09M 48.68M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($1.91) $0.00 ($4.80) ($5.12) ($5.90) ($4.96) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 2.31M 0.00 15.75M 20.53M 21.78M 22.35M 23.44M 34.12M 46.09M 48.68M
Normalized Net Operating Profit after Tax (NOPAT)		 -8.69 0.56 -14 -54 -77 -89 -65 -55 -46 -68 -87
Debt Service Ratios		 - - - - - - - - - - -
Payout Ratios		 - - - - - - - - - - -

Quarterly Metrics And Ratios for Urogen Pharma

This table displays calculated financial ratios and metrics derived from Urogen Pharma's official financial filings.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
DEI Shares Outstanding		 - - - - - - - - 46,808,892.00 48,682,280.00 48,721,701.00
DEI Adjusted Shares Outstanding		 - - - - - - - - 46,808,892.00 48,682,280.00 48,721,701.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - - -0.56 -0.48 -0.29
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 30.06% 9.24% 3.35% 20.87% 4.40% 7.84% 10.83% 9.04% - 151.60% 199.22%
EBITDA Growth		 14.89% -20.19% -55.18% -35.85% -65.58% -28.60% -46.26% -28.42% - 46.58% 89.47%
EBIT Growth		 20.70% -15.15% -52.52% -23.61% -67.65% -32.16% -45.81% -36.43% - 40.31% 90.38%
NOPAT Growth		 27.97% -16.76% -67.98% -29.96% -89.32% -43.41% -60.41% -56.09% - 45.11% 100.27%
Net Income Growth		 9.88% -6.86% -38.39% -8.20% -44.19% -35.80% -49.51% -40.87% - 46.23% 71.26%
EPS Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Operating Cash Flow Growth		 40.25% -22.97% -17.14% -59.92% -4.79% -32.42% -67.70% -52.80% - -7.83% 17.12%
Free Cash Flow Firm Growth		 225.08% -0.84% -115.17% -493.74% -87.10% -126.33% -3,265.84% -359.54% - -516.05% -521.85%
Invested Capital Growth		 -16.71% -13.97% -18.36% -9.95% -18.50% -13.92% -14.14% -7.16% - 42.47% 61.47%
Revenue Q/Q Growth		 12.84% -20.18% 16.33% 15.36% -2.54% -17.55% 19.56% 13.49% - 34.68% 42.18%
EBITDA Q/Q Growth		 -14.60% -60.41% 2.39% 20.89% -39.69% -19.22% -11.02% 30.54% - 4.12% 78.13%
EBIT Q/Q Growth		 -5.98% -56.11% -0.68% 25.79% -43.74% -23.06% -11.07% 30.56% - -4.20% 82.10%
NOPAT Q/Q Growth		 -8.21% -76.19% -0.38% 32.10% -57.64% -33.47% -12.28% 33.93% - -6.01% 100.55%
Net Income Q/Q Growth		 -18.91% -24.10% -3.46% 29.13% -58.46% -16.88% -13.91% 33.23% - 10.58% 39.12%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 24.87% -144.19% 25.17% -16.49% 50.77% -208.57% 5.23% -6.14% - -18.24% 27.16%
Free Cash Flow Firm Q/Q Growth		 737.19% -177.84% 91.98% -549.88% 127.43% -1,684.06% -19.21% 11.27% - -55.98% -20.34%
Invested Capital Q/Q Growth		 -10.05% 0.97% -5.58% 5.18% -18.60% 4.06% -5.79% 10.98% - 28.52% 29.14%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 90.28% 90.80% 89.80% 90.27% 89.94% 88.50% 85.34% 88.07% - 91.88% 90.93%
EBITDA Margin		 -89.13% -171.41% -143.83% -98.64% -141.36% -204.40% -189.81% -116.17% - -43.40% -6.68%
Operating Margin		 -62.09% -137.05% -118.27% -69.61% -112.59% -182.26% -171.17% -99.65% - -39.76% 0.15%
EBIT Margin		 -85.48% -167.19% -144.69% -93.08% -137.27% -204.88% -190.34% -116.47% - -48.61% -6.12%
Profit (Net Income) Margin		 -110.57% -171.91% -152.89% -93.93% -152.71% -216.47% -206.24% -121.34% - -46.26% -19.81%
Tax Burden Percent		 117.39% 100.17% 100.11% 100.39% 107.60% 100.90% 102.07% 96.94% - 83.17% 164.54%
Interest Burden Percent		 110.18% 102.65% 105.55% 100.52% 103.39% 104.71% 106.15% 107.48% - 114.44% 196.71%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Return on Equity (ROE)		 132.29% 133.15% 210.11% 1,400.39% 342.83% 319.73% 491.48% 366.31% - 156.08% 86.49%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Operating Return on Assets (OROA)		 -45.05% -89.91% -65.22% -33.57% -53.49% -83.99% -73.13% -46.16% - -27.24% -5.01%
Return on Assets (ROA)		 -58.26% -92.45% -68.91% -33.87% -59.50% -88.74% -79.24% -48.10% - -25.93% -16.21%
Return on Common Equity (ROCE)		 132.29% 133.15% 210.11% 1,400.39% 342.83% 319.73% 491.48% 366.31% - 156.08% 86.49%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 259.92% -374.69% -452.20% 0.00% 297.97% 0.00% 0.00% - 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -10 -18 -18 -12 -19 -26 -29 -19 -13 -14 0.08
NOPAT Margin		 -43.46% -95.94% -82.79% -48.73% -78.81% -127.58% -119.82% -69.76% - -27.83% 0.11%
Net Nonoperating Expense Percent (NNEP)		 -67.79% -61.63% -29.89% -11.98% -22.31% -24.88% -23.07% -21.11% - -80.57% 63.75%
Return On Investment Capital (ROIC_SIMPLE)		 -29.92% - - - -16.90% -32.92% -89.15% -148.10% -58.54% -20.00% 0.13%
Cost of Revenue to Revenue		 9.72% 9.20% 10.20% 9.73% 10.06% 11.50% 14.66% 11.93% - 8.12% 9.07%
SG&A Expenses to Revenue		 104.34% 145.35% 137.57% 114.83% 141.90% 172.64% 178.40% 136.75% - 101.03% 66.85%
R&D to Revenue		 48.03% 82.50% 70.50% 45.05% 60.63% 98.11% 78.11% 50.97% - 30.61% 23.93%
Operating Expenses to Revenue		 152.37% 227.85% 208.06% 159.88% 202.53% 270.75% 256.51% 187.72% - 131.64% 90.78%
Earnings before Interest and Taxes (EBIT)		 -20 -31 -32 -23 -34 -41 -46 -32 -24 -25 -4.43
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -21 -32 -31 -25 -35 -41 -46 -32 -23 -22 -4.84
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 20.00 20.96 0.00 0.00 0.00 0.00 - 0.00 0.00
Price to Tangible Book Value (P/TBV)		 0.00 0.00 20.00 20.96 0.00 0.00 0.00 0.00 - 0.00 0.00
Price to Revenue (P/Rev)		 5.60 6.07 7.13 5.99 4.97 5.55 6.70 9.56 - 6.23 9.50
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 5.08 5.27 5.43 4.49 3.65 4.71 6.31 9.56 - 6.61 9.94
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 -1.52 -2.43 3.23 4.77 -14.02 -2.69 -1.35 -1.11 - -1.57 -1.45
Long-Term Debt to Equity		 -1.52 -2.43 3.23 4.77 -14.02 -2.69 -1.35 -1.11 - -1.57 -1.45
Financial Leverage		 0.30 0.30 0.95 11.54 2.20 1.67 2.88 1.49 - 0.14 -0.20
Leverage Ratio		 -2.03 -2.00 -3.49 -30.08 -6.27 -5.18 -7.78 -5.42 - -2.94 -2.04
Compound Leverage Factor		 -2.24 -2.05 -3.68 -30.23 -6.48 -5.42 -8.26 -5.82 - -3.36 -4.02
Debt to Total Capital		 290.77% 169.85% 76.34% 82.67% 107.68% 159.19% 386.91% 991.59% - 275.19% 323.35%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Long-Term Debt to Total Capital		 290.77% 169.85% 76.34% 82.67% 107.68% 159.19% 386.91% 991.59% - 275.19% 323.35%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Common Equity to Total Capital		 -190.77% -69.85% 23.66% 17.33% -7.68% -59.19% -286.91% -891.59% - -175.19% -223.35%
Debt to EBITDA		 -1.15 -1.07 -0.96 -1.12 -1.00 -0.94 -0.86 -0.83 - -1.59 -2.34
Net Debt to EBITDA		 0.50 0.75 1.42 1.23 0.97 0.58 0.25 0.00 - -0.43 -1.00
Long-Term Debt to EBITDA		 -1.15 -1.07 -0.96 -1.12 -1.00 -0.94 -0.86 -0.83 - -1.59 -2.34
Debt to NOPAT		 -2.17 -2.01 -1.75 -2.08 -1.82 -1.65 -1.46 -1.37 - -2.58 -4.11
Net Debt to NOPAT		 0.94 1.40 2.59 2.28 1.77 1.02 0.43 0.01 - -0.71 -1.76
Long-Term Debt to NOPAT		 -2.17 -2.01 -1.75 -2.08 -1.82 -1.65 -1.46 -1.37 - -2.58 -4.11
Altman Z-Score		 -3.17 -2.77 -1.28 -1.32 -2.14 -3.00 -4.20 -4.45 - -2.92 -1.22
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 5.42 7.47 8.15 9.00 6.01 5.65 4.14 3.99 - 4.69 3.80
Quick Ratio		 4.88 6.77 7.55 8.31 5.59 5.13 3.71 3.47 - 3.86 3.18
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 5.28 -4.77 -0.38 -2.48 0.68 -11 -13 -11 -43 -66 -80
Operating Cash Flow to CapEx		 -23,207.14% 0.00% -28,271.43% -28,816.67% -11,842.61% -95,509.09% -28,244.68% -48,586.21% - -83,918.52% -55,010.00%
Free Cash Flow to Firm to Interest Expense		 1.47 -1.95 -0.11 -0.91 0.18 -2.65 -3.11 -3.38 - -15.89 -16.37
Operating Cash Flow to Interest Expense		 -3.62 -12.97 -6.86 -10.17 -3.50 -10.33 -9.64 -12.53 - -10.83 -6.75
Operating Cash Flow Less CapEx to Interest Expense		 -3.64 -12.97 -6.89 -10.20 -3.53 -10.34 -9.67 -12.56 - -10.84 -6.77
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.53 0.54 0.45 0.36 0.39 0.41 0.38 0.40 - 0.56 0.82
Accounts Receivable Turnover		 5.88 6.33 5.16 5.01 5.06 5.44 5.09 4.54 - 3.74 3.48
Inventory Turnover		 1.87 1.39 1.39 1.38 1.19 1.28 1.48 1.46 - 1.00 1.09
Fixed Asset Turnover		 83.30 101.02 114.11 124.90 134.52 154.02 148.64 148.14 - 226.05 293.75
Accounts Payable Turnover		 0.65 0.50 0.43 0.52 0.40 0.39 0.39 0.51 - 0.43 0.49
Days Sales Outstanding (DSO)		 62.10 57.70 70.67 72.80 72.16 67.14 71.78 80.37 - 97.49 104.83
Days Inventory Outstanding (DIO)		 194.92 262.85 263.47 264.35 306.19 285.46 246.11 250.08 - 364.99 335.01
Days Payable Outstanding (DPO)		 563.84 729.83 851.18 708.68 903.54 933.00 924.26 719.67 - 840.66 748.96
Cash Conversion Cycle (CCC)		 -306.81 -409.29 -517.04 -371.53 -525.19 -580.40 -606.36 -389.23 - -378.18 -309.12
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -108 -108 -114 -108 -128 -123 -130 -116 -99 -71 -50
Invested Capital Turnover		 -0.82 -0.83 -0.81 -0.86 -0.76 -0.79 -0.77 -0.86 - -1.45 -2.09
Increase / (Decrease) in Invested Capital		 -16 -13 -18 -9.80 -20 -15 -16 -7.75 29 52 80
Enterprise Value (EV)		 420 444 462 401 330 433 595 922 - 929 1,875
Market Capitalization		 463 512 606 535 449 510 632 923 - 875 1,793
Book Value per Share		 ($2.11) ($1.18) $0.84 $0.61 ($0.21) ($1.01) ($2.03) ($2.49) ($2.25) ($2.55) ($2.72)
Tangible Book Value per Share		 ($2.11) ($1.18) $0.84 $0.61 ($0.21) ($1.01) ($2.03) ($2.49) ($2.25) ($2.55) ($2.72)
Total Capital		 34 57 128 147 115 78 33 13 23 71 59
Total Debt		 99 98 98 122 123 125 126 128 128 195 192
Total Long-Term Debt		 99 98 98 122 123 125 126 128 128 195 192
Net Debt		 -43 -68 -144 -134 -120 -77 -37 -0.59 6.35 53 82
Capital Expenditures (CapEx)		 0.06 0.00 0.08 0.10 0.12 0.04 0.14 0.09 0.02 0.05 0.06
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.19 5.55 2.84 12 -7.58 -1.79 -8.72 -2.08 18 45 64
Debt-free Net Working Capital (DFNWC)		 138 170 245 262 230 195 149 126 140 187 174
Net Working Capital (NWC)		 138 170 245 262 230 195 149 126 140 187 174
Net Nonoperating Expense (NNE)		 16 14 15 11 18 18 21 14 13 9.39 14
Net Nonoperating Obligations (NNO)		 -43 -68 -144 -134 -120 -77 -37 -0.59 6.35 53 82
Total Depreciation and Amortization (D&A)		 -0.86 -0.79 0.19 -1.40 -1.01 0.10 0.13 0.08 0.70 2.65 -0.40
Debt-free, Cash-free Net Working Capital to Revenue		 0.22% 6.59% 3.34% 13.05% -8.38% -1.95% -9.25% -2.15% - 32.19% 34.02%
Debt-free Net Working Capital to Revenue		 166.81% 202.15% 287.90% 293.53% 254.64% 212.45% 158.45% 130.86% - 132.98% 91.93%
Net Working Capital to Revenue		 166.81% 202.15% 287.90% 293.53% 254.64% 212.45% 158.45% 130.86% - 132.98% 91.93%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.54) ($0.97) ($0.91) ($0.55) ($0.53) ($0.92) ($1.05) ($0.69) ($0.53) ($0.47) ($0.28)
Adjusted Weighted Average Basic Shares Outstanding		 28.83M 33.38M 36.82M 43.10M 42.88M 47.42M 47.74M 48.06M 48.12M 50.18M 50.38M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Diluted Shares Outstanding		 34.12M 36.13M 42.11M 42.20M 46.09M 46.11M 46.26M 46.81M 48.68M 48.72M 48.88M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 34.12M 36.13M 42.11M 42.20M 46.09M 46.11M 46.26M 46.81M 48.68M 48.72M 48.88M
Normalized Net Operating Profit after Tax (NOPAT)		 -10 -18 -18 -12 -19 -26 -29 -19 -13 -14 0.08
Normalized NOPAT Margin		 -43.46% -95.94% -82.79% -48.73% -78.81% -127.58% -119.82% -69.76% - -27.83% 0.11%
Pre Tax Income Margin		 -94.19% -171.62% -152.71% -93.56% -141.92% -214.53% -202.04% -125.18% - -55.63% -12.04%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -5.61 -12.83 -9.13 -8.62 -8.66 -10.20 -11.15 -9.49 - -5.92 -0.91
NOPAT to Interest Expense		 -2.85 -7.36 -5.23 -4.51 -4.97 -6.35 -7.02 -5.68 - -3.39 0.02
EBIT Less CapEx to Interest Expense		 -5.62 -12.83 -9.16 -8.66 -8.69 -10.21 -11.19 -9.52 - -5.93 -0.92
NOPAT Less CapEx to Interest Expense		 -2.87 -7.36 -5.25 -4.55 -5.00 -6.36 -7.06 -5.71 - -3.40 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

UroGen Pharma’s financial results show a meaningful improvement in commercial performance, but the company remains unprofitable, cash-flow negative and highly leveraged. Revenue reached $72.5 million in Q2 2026, up from $24.2 million in Q2 2025 and $50.96 million in Q1 2026. Gross profit increased to $65.9 million, producing a gross margin of approximately 91%, compared with about 85% a year earlier.

The stronger revenue base is beginning to improve operating leverage. UroGen reported operating income of approximately $0.1 million in Q2 2026, compared with operating losses of $20.3 million in Q1 2026 and $41.4 million in Q2 2025. Selling, general and administrative expense declined sequentially and year over year, although research and development spending increased to $17.3 million.

Despite the operating improvement, UroGen still posted a net loss attributable to common shareholders of $14.4 million, or $0.28 per basic share, in Q2 2026. The loss was narrower than the $23.6 million loss in Q1 2026 and the $49.9 million loss in Q2 2025. However, interest expense increased to $4.9 million, while other net expense was $4.5 million, limiting the benefit of near-break-even operating results.

Cash usage remains a major concern. Operating cash outflow improved to $33.0 million in Q2 2026 from $39.8 million in Q2 2025, but the company continued to consume cash. The first half of 2026 generated operating cash outflow of approximately $78.3 million. Q2 cash flow was also pressured by a $24.6 million unfavorable change in operating assets and liabilities.

At June 30, 2026, UroGen had $79.1 million of cash and equivalents, $28.8 million of short-term investments and $1.3 million of restricted cash. This represents approximately $109.2 million of immediately available cash and short-term investments, down from roughly $159.0 million at June 30, 2025. Accounts receivable increased sharply to $88.8 million, which may support future cash collections but also contributed to working-capital use.

The balance sheet remains weak. Total liabilities of $385.0 million exceeded total assets of $252.6 million, resulting in negative shareholders’ equity of $132.4 million. Long-term debt stood at $188.7 million, excluding $2.9 million of capital lease obligations. This leverage creates substantial refinancing and interest-rate risk as the company works toward sustainable profitability.

  • Revenue growth is accelerating: Q2 2026 revenue increased approximately 199% year over year and 42% sequentially.
  • Operating performance improved substantially: UroGen moved from a $20.3 million operating loss in Q1 2026 to roughly breakeven in Q2, supported by higher revenue and lower selling, general and administrative expense.
  • Gross margins remain strong: The Q2 2026 gross margin was approximately 91%, indicating favorable economics on reported product sales.
  • Net losses are narrowing: The quarterly net loss declined to $14.4 million from $23.6 million in Q1 2026 and $49.9 million in Q2 2025.
  • Liquidity remains adequate in the near term: Cash, restricted cash and short-term investments totaled approximately $109.2 million at the end of Q2 2026, while current assets were about $235.4 million versus $61.9 million of current liabilities.
  • Accounts receivable and inventory increased: These balances may reflect expanding commercial activity, but they also tied up capital and contributed to the $24.6 million working-capital cash outflow in Q2.
  • Investment activity continues to affect cash balances: UroGen generated $1.7 million from investing activities in Q2 2026, primarily through investment maturities, while prior quarters included sizable purchases and sales of investments.
  • Operating cash flow remains negative: The company used $33.0 million in operating cash during Q2 and approximately $78.3 million during the first half of 2026.
  • Leverage is elevated: Long-term debt and lease obligations totaled approximately $191.7 million, while quarterly interest expense rose to $4.9 million.
  • Shareholder capital remains impaired: Negative equity reached $132.4 million, and weighted-average basic shares increased to 50.4 million in Q2 2026 from 40.5 million in Q2 2024, indicating meaningful dilution over the period.

Overall, the income statement is trending in a more favorable direction as revenue scales and operating losses narrow. However, investors should monitor whether this improvement converts into positive operating cash flow, whether accounts receivable are collected promptly, and whether additional debt or equity financing is required. The combination of negative equity, significant debt and continued cash burn keeps Urogen Pharma a high-risk investment despite its stronger recent revenue performance.

09/03/26 03:13 PM ETAI Generated. May Contain Errors.

Urogen Pharma Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Urogen Pharma's fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Urogen Pharma's net income appears to be on an upward trend, with a most recent value of -$153.49 million in 2025, rising from -$12.69 million in 2015. The previous period was -$126.87 million in 2024. Find out what analysts predict for Urogen Pharma in the coming months.

Urogen Pharma's total operating income in 2025 was -$124.86 million, based on the following breakdown:
  • Total Gross Profit: $97.34 million
  • Total Operating Expenses: $222.20 million

Over the last 10 years, Urogen Pharma's total revenue changed from $0.00 in 2015 to $109.79 million in 2025, a change of 10,978,800,000.0%.

Urogen Pharma's total liabilities were at $305.93 million at the end of 2025, a 3.9% increase from 2024, and a 4,433.0% increase since 2016.

In the past 9 years, Urogen Pharma's cash and equivalents has ranged from $21.36 million in 2016 to $171.99 million in 2024, and is currently $110.75 million as of their latest financial filing in 2025.

Over the last 10 years, Urogen Pharma's book value per share changed from 0.00 in 2015 to -2.25 in 2025, a change of -225.3%.


Related Companies

Financial statements for NASDAQ:URGN last updated on 8/5/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...
Chaikin Analytics | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel